Pfizer Reports Positive Results For Rheumatoid Arthritis
Published: 11-Jun-2009
CP-690,550, an oral, selective, potent inhibitor of JAK family of enzymes
Pfizer has announced that data from two new mid-stage clinical studies of oral JAK-3 inhibitor, CP-690,550, showed statistically significant response, versus placebo for patients with rheumatoid arthritis (RA).
CP-690,550 is an oral, selective, potent inhibitor of the JAK family of enzymes, which are involved in numerous inflammatory and autoimmune diseases, including RA.
Data from these two phase-II trials and one ongoing open-label safety study, will be presented this week at the 10th Annual Congress of the European League Against Rheumatism (EULAR). These results confirm findings from two previously reported Phase-II studies in RA and have been used to support dose selection for Phase-III.
Network Sites

Suppliers To This Sector
Browse A-Z
World Courier
Offering Fully-Integrated GxP-Compliant Global Transport and Storage for the Pharmaceutical Industry...
WebWise Learning
Turning Information into Working Knowledge ...
Vetter Pharma International
High-Quality Aseptically Pre-Filled Injection Systems, Cartridges and Vials ...
Valsynthese
Hazardous Chemistry in Safe Hands ...
USB
Products from Affymetrix ...
Umicore Precious Metals Chemistry
Chemicals and Catalysts for Industrial Applications ...
White Papers
Browse A-Z
CaseBase Management
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
SafetyBase Interchange
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
ClinicalBase Trial
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
Reliable Prediction of White Plasma Levels
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
Kinetics and Metabolism
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
Drug Safety Evaluation
Our kinetics & metabolism experts can help you select and further develop your candidate d ...


Delicious
Digg
Reddit
Stumble
LinkedIn
Mail sent successfully